The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

Direxion Daily FTSE China Bull 3X Shares (NYSEARCA:YINN – Get Free Report)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $25.78, but opened at $27.85.

We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

which was cleared in China for TNBC in 2022. The approval means Kelun has brought its TROP2 ADC to market ahead of ...

The latest health news includes studies on medications for thyroid issues and breast cancer, the healthcare industry's ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855), a global biopharmaceutical company ...

Americans are big buyers of British exports such as Land Rovers, machinery, chemicals and a string of blockbuster pharmaceuticals—a special relationship that leaves UK companies particularly exposed ...

(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...